drugset / Trial / NCT00260208
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
RandomizedParallel-groupOpen-labelPrevention
Summary
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this study was to see if the frequency of liver fibrosis was different with cyclosporine microemulsion than tacrolimus
Timeline
- Start
- 2006-01
- Primary completion
- 2010-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 10 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 15 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.1 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.15 mg/kg | Oral |